Oriental Bio: Net profit in 2021 is expected to increase by 181%-205% year-on-year _ Securities Times Network

Securities Times e Company News, Oriental Bio (688298) disclosed its performance forecast on the evening of January 14. It is expected that the net profit in 2021 will be 4.72 billion yuan to 5.12 billion yuan, a year-on-year increase of 181.45%-205.31%; the company’s new coronavirus antigen rapid detection reagent ( Including home self-test) product sales in the European market continued to grow significantly, prompting a significant increase in operating performance in 2021. The company announced on the same day that the company paid attention to the release of the “New Crown Rapid Testing Program in the United States, Fostering a New Blue Ocean for Antigen Testing, Raising the Target Price” released by the research department of CITIC Securities, and made a profit forecast for the company’s performance from 2022 to 2023. The report is only for CITIC Securities research. The opinions of the Ministry do not represent the position of the company. The company has not provided relevant operating performance data that has not been disclosed to the outside world; nor has it made any forecasts of operating performance for 2022-2023.